Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow

Finegold, 2010, Immunotherapy throughout the decades: from noon to now, Ann Allergy Asthma Immunol, 105, 328, 10.1016/j.anai.2010.08.008 Shahani, 2012, Immunotherapy in clinical medicine: historical perspective and current status, Med Clin N Am, 96, 421, 10.1016/j.mcna.2012.04.001 Shakir, 2010, Mechanisms of immunotherapy: a historical perspective, Ann Allergy Asthma Immunol, 105, 340, 10.1016/j.anai.2010.09.012 Graham, 2015, History of passive antibody administration for prevention and treatment of infectious diseases, Curr Opin HIV AIDS, 10, 129, 10.1097/COH.0000000000000154 Rambar, 1946, Convalescent serum and pooled plasma in communicable diseases, US Nav Med Bull, 46, 93 Kak, 2012, Immunotherapies in infectious diseases, Med Clin N Am, 96, 455, 10.1016/j.mcna.2012.04.002 Hsu, 2011, Polyclonal immunoglobulins and hyperimmune globulins in prevention and management of infectious diseases, Infect Dis Clin N Am, 25, 773, 10.1016/j.idc.2011.07.005 Lachman, 2012, The use of antibodies in the prophylaxis and treatment of infections, Emerg Microbes Infect, 1, 10.1038/emi.2012.2 Finegold, 2010, Immunotherapy: the next 100 years, Ann Allergy Asthma Immunol, 105, 394, 10.1016/j.anai.2010.09.002 Mahanty, 2005, Emerging and re-emerging pathogens: immunological aspects of viral hemorrhagic fevers, 99 Peigue-Lafeuille, 2004, La rage humaine en France en 2004 : état des lieux et prise en charge, Med Mal Infect, 34, 551, 10.1016/j.medmal.2004.07.031 Couderc, 2009, Prophylaxis and therapy for Chikungunya virus infection, J Infect Dis, 200, 516, 10.1086/600381 Tsarev, 1994, Successful passive and active immunization of cynomolgus monkeys against hepatitis E, Proc Natl Acad Sci U S A, 91, 10198, 10.1073/pnas.91.21.10198 McHardy, 1980, Passive protection of mice against infection with Trypanosoma cruzi with plasma: the use of blood- and vector-bug derived trypomastogote challenge, Parasitology, 80, 471, 10.1017/S0031182000000937 Avenard, 1979, Prévention de la varicelle chez les enfants à haut risque. Efficacité comparée des immunoglobulines spécifiques et du plasma défibriné de convalescent (414 cas), Nouv Presse Med, 8, 673 Luke, 2006, Convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?, Ann Int Med, 145, 599, 10.7326/0003-4819-145-8-200610170-00139 Zingher, 2005, Convalescent whole blood, plasma and serum in the prophylaxis of measles, Rev Med Virol, 15, 407, 10.1002/rmv.480 Young, 2014, Post-exposure passive immunization for preventing measles, Cochrane Database Syst Rev, 4, CD010056 Jahrling, 1984, Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain, Infect Immun, 44, 528, 10.1128/IAI.44.2.528-533.1984 Frame, 1984, The use of Lassa fever convalescent plasma in Nigeria, Trans R Soc Trop Med Hyg, 78, 319, 10.1016/0035-9203(84)90107-X McCormick, 1986, Lassa fever. Effective therapy with ribavirin, N Engl J Med, 314, 20, 10.1056/NEJM198601023140104 Jahrling, 1985, Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization, Trans R Soc Med Hyg, 79, 380, 10.1016/0035-9203(85)90388-8 Gouwen, 2011, Progress in the experimentally therapy of severe arenaviral infections, Future Microbiol, 6, 1429, 10.2217/fmb.11.132 Peters, 1996, Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator, Antiviral Res, 6, 285, 10.1016/0166-3542(86)90024-0 Ye, 2004, Neutralizing antibodies and Sin Nombre virus RNA after recovery from Hantavirus cardiopulmonary syndrome, Emerg Infect Dis, 10, 478 Klingström, 2008, Passive immunization protects cynomolgus macaques against Puumala hantavirus challenge, Antivir Ther, 13, 125, 10.1177/135965350801300114 Shayan, 2015, Crimean-Congo hemorrhagic fever, Lab Med, 46, 180, 10.1309/LMN1P2FRZ7BKZSCO Heshmati, 1992, 7 Lefrère, 1996, Quantitation of passively acquired human immunodeficiency virus (HIV) antibodies in AIDS patients transfused with a plasma rich in HIV antibodies, Transfusion, 36, 734, 10.1046/j.1537-2995.1996.36896374379.x Morand-Joubert, 1997, Virological and immunological data of AIDS patients treated by passive immunotherapy (transfusions of plasma rich in HIV-1 antibodies, Vox Sang, 73, 149, 10.1046/j.1423-0410.1997.7330149.x Lefrère, 1991, Immunothérapie passive dans le SIDA : transfusion de plasma riche en anticorps anti-p25 (essai de phase I), Rev Fr Transfus Hemobiol, 34, 199 Yeh, 2005, Experience using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital, J Antimicrob Chemother, 56, 919, 10.1093/jac/dki346 Wong, 2003, Treatment of severe acute respiratory syndrome with convalescent plasma, Hong Kong Med J, 9, 199 Zhang, 2005, Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma, Transfusion, 45, 1160, 10.1111/j.1537-2995.2005.00179.x Cheng, 2005, Use of convalescent plasma therapy in SARS patients in Hong-Kong, Eur J Clin Microbiol Infect Dis, 24, 44, 10.1007/s10096-004-1271-9 Soo, 2004, Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients, Clin Microbiol Infect, 10, 676, 10.1111/j.1469-0691.2004.00956.x Wong, 2008, The management of coronavirus infections with particular reference to SARS, J Antimicrob Chemother, 62, 437, 10.1093/jac/dkn243 Stockman, 2006, SARS: systematic review of treatment effects, PloS Med, 3, e343, 10.1371/journal.pmed.0030343 Mair-Jenkins, 2015, The effectiveness of convalescent plasma and hyperimmune immunolobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis, J Infect Dis, 211, 80, 10.1093/infdis/jiu396 Hui, 2013, Severe acute respiratory syndrome (SARS): lessons learnt in Hong-Kong, J Thorac Dis, 5, S122 Zhou, 2007, Treatment with convalescent plasma for influenza A (H5N1) infection, N Engl J Med, 357, 1450, 10.1056/NEJMc070359 Kong, 2006, Successful treatment of avian influenza with convalescent plasma (Letter), Hong Kong Med J, 12, 489 Hui, 2013, Adjunctive therapies and immunomodulatory agents in the management of severe influenza, Antiviral Res, 98, 410, 10.1016/j.antiviral.2013.03.019 Luke, 2010, Hark back: passive immunotherapy for influenza and other serious infections, Crit Care Med, 38, e66, 10.1097/CCM.0b013e3181d44c1e Beigel, 2012, A study in scarlet: convalescent plasma for severe influenza, Crit Care Med, 40, 1027, 10.1097/CCM.0b013e31823d77c3 Hohenadl, 2014, Hyperimmune intravenous immunoglobulins containing high titres of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice, Virol J, 11, 70, 10.1186/1743-422X-11-70 Ortiz, 2013, Clinical research during a public health emergency: a systematic review of severe pandemic influenza management, Crit Care Med, 41, 1345, 10.1097/CCM.0b013e3182771386 Hung, 2011, Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection, Clin Infect Dis, 52, 447, 10.1093/cid/ciq106 Wong, 2010, Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection, Transfusion, 50, 1967, 10.1111/j.1537-2995.2010.02651.x Kreil, 2012, Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenza, Transfusion, 52, 803, 10.1111/j.1537-2995.2011.03347.x Parry, 2012, Strategies for screening blood donors to source convalescent H1N1v plasma for intervention therapy, Vox Sang, 103, 107, 10.1111/j.1423-0410.2012.01599.x Wu, 2013, The epidemiological and public health research response to 2009 pandemic influenza (H1N1): experiences from Hong-Kong, Influenza Other Respir Viruses, 7, 367, 10.1111/j.1750-2659.2012.00420.x Hung, 2013, Hyperimmune IV immunoglobulin treatment. A multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection, Chest, 144, 464, 10.1378/chest.12-2907 Gupta, 2001, Passive transfer of antibodies protect immunocompetent and immunodeficient mice against letal Ebola virus infection without complete inhibition of viral replication, J Virol, 75, 4649, 10.1128/JVI.75.10.4649-4654.2001 Colebunders, 2015, Large-scale convalescent blood and plasma transfusion therapy for Ebola virus disease, J Infect Dis, 211, 1208 Gutfraind, 2015, Evaluating large-scale blood transfusion therapy for the current Ebola epidemic in Liberia, J Infect Dis, 211, 1262, 10.1093/infdis/jiv042 van Griensven, 2015, The use of Ebola convalescent plasma to treat Ebola virus disease in resource-constrained settings: a perspective from the field, Clin Infect Dis Lu, 2014, Using convalescent whole blood of plasma as passive immune therapy for global war against Ebola, Emerg Microbes Infect, 3, e80, 10.1038/emi.2014.86 Garraud, 2014, World Apheresis Association letter to the WHO: the World Apheresis Association urges the development of preparedness plans to make specific plasma available when urgently needed, Transfus Apher Sci, 51, 2, 10.1016/j.transci.2014.11.007 Burnouf, 2014, Ebola virus convalescent blood products: where we are now and where we may need to go, Transfus Apher Sci, 51, 120, 10.1016/j.transci.2014.10.003 Burnouf, 2014, Ebola: a call for blood transfusion strategy in sub-Saharan Africa, Lancet, 384, 1347, 10.1016/S0140-6736(14)61693-7 Kraft, 2015, The use of TKM-100802 a convalescent plasma in 2 patients with Ebola virus disease in the United States, Clin Infect Dis, 61, 496, 10.1093/cid/civ334 Abela, 2010, Therapeutic antibodies in HIV treatment: classical approaches to novel advances, Curr Pharm Des, 16, 3754, 10.2174/138161210794079245 Flingai, 2015, Protection against dengue disease by synthetic nucleic acid antibody therapy, Sci Rep, 5, 12616, 10.1038/srep12616 Martina, 2014, Dengue pathogenesis: a disease driven by the host response, Sci Prog, 97, 197, 10.3184/003685014X14049173153889 Brailsford, 2015, Blood Donor Selection Steering Group of the Advisory Committee for the Safety of Blood, Tissues, Organs. Who should donate blood? Policy decisions on donor deferral criteria should protect recipients and be fair to donors, Transfus Med, 25, 234, 10.1111/tme.12225